Status:
UNKNOWN
Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer.
Lead Sponsor:
Fifth Affiliated Hospital, Sun Yat-Sen University
Conditions:
Positron-Emission Tomography
Lymph Node Metastases
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The aim of this study is to make up for the gap by performing a dynamic scan of \<Sup\>18\<Sup\>F-FDG PET/CT on newly diagnosed patients with papillary thyroid carcinoma. Pathological and genomic stud...
Detailed Description
Thyroid cancer is the most common malignant tumor in human endocrine system, accounting for 0.2% \~ 1.0% of malignant tumors .According to the global cancer report released by the world health organiz...
Eligibility Criteria
Inclusion
- • Accurately diagnosing primary papillary thyroid cancer according to pathological diagnostic criteria .
- Thyroid papillary carcinoma was suspected by thyroid ultrasound text and/or neck CT.
- The age is more than 18 years old and less than 65 years old. There is no gender restriction.
- Untreated patients who have not received surgery, interventional therapy,chemotherapy, biotherapy, and radiation therapy.
- Physical condition score of Eastern Cooperative Oncology Group（ECOG）: 0-2; no major organ dysfunction; oxygen partial pressure ≥ 10.64 kilopascal（kPa）; white blood cell count≥ 4 × 109/L; hemoglobin≥ 9.5g/dL; neutrophil absolute count ≥ 1.5 × 109 / L; platelet count ≥ 100× 109 / L; total bilirubin ≤ 1.5 times of the upper limit of normal value;creatinine ≤ 1.25 times of the upper limit of normal value; and creatinine clearance ≥ 60ml / min.
- Be able to obtain complete follow-up information, understand the situation of this study and sign informed consent.
Exclusion
- • Poorly controlled diabetics (fasting blood glucose levels \> 200 mg/dL).• In addition to four types of malignant tumors that can be treated with radical resection, such as cervical cancer in situ, basal or squamous cell skin cancer, (breast) ductal carcinoma in situ, and organ localized prostate cancer, suffering from any other malignant tumors within 5 years.• Breastfeeding and/or pregnant women.
- Patients with severe bleeding tendencies (prothrombin time less than 50%,cannot be corrected by treatment with vitamin K, etc.).
- Recent severe hemoptysis, severe cough, dyspnea or patients are not able to cooperate.
- People with severe emphysema, pulmonary congestion, and pulmonary heart disease.
- Researchers believe that the subject may not be able to complete this study or may not be able to comply with the requirements of this study (for management reasons or other reasons).
Key Trial Info
Start Date :
November 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03830242
Start Date
November 1 2018
End Date
December 31 2024
Last Update
July 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fifth Affiliated Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, China